Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers
- Conditions
- Healthy
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00426452
Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine
- Conditions
- Healthy
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00426036
- Locations
- 🇨🇿
Novartis Investigative site, Prague, Czech Republic
Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00426179
- Locations
- 🇬🇧
Novartis Investigative site, Horsham, United Kingdom
Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2008-08-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00426478
- Locations
- 🇨🇳
National Taiwan University, Taipei, R.o.c, Taiwan
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 274
- Registration Number
- NCT00424346
- Locations
- 🇪🇸
Novartis, Barcelona, Spain
🇺🇸Sun Valley Arthritis Center, Ltd, Peoria, Arizona, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
- Conditions
- Healthy
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 16
- Registration Number
- NCT00424671
- Locations
- 🇨🇿
Novartis Investigative site, Prague, Czech Republic
Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 34
- Registration Number
- NCT00424541
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
- Conditions
- COPD
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00422552
- Locations
- 🇬🇧
Novartis Investigative site, Horsham, United Kingdom
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312
- Conditions
- Healthy
- First Posted Date
- 2007-01-15
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 63
- Registration Number
- NCT00422175
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).
- Conditions
- Health Postmenopausal Women
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 38
- Registration Number
- NCT00421590
- Locations
- 🇩🇰
Novartis Investigative site, Copenhagen, Denmark